Risk of stroke early after implantation of a left ventricular assist device.


Journal

The Journal of thoracic and cardiovascular surgery
ISSN: 1097-685X
Titre abrégé: J Thorac Cardiovasc Surg
Pays: United States
ID NLM: 0376343

Informations de publication

Date de publication:
01 2019
Historique:
received: 13 12 2017
revised: 24 05 2018
accepted: 06 06 2018
pubmed: 1 8 2018
medline: 8 10 2019
entrez: 1 8 2018
Statut: ppublish

Résumé

Stroke is one of the major adverse events after left ventricular assist device implantation. Risk of stroke is the highest immediately after left ventricular assist device implantation and then increases again in chronic periods. There is no study that has analyzed risk factors for stroke in acute phase. We investigated the risk factors for stroke in the acute phase after left ventricular assist device implantation in the present study. Between October 2005 and December 2016, 158 consecutive patients (mean age, 43 ± 14 years; 34% were women) underwent continuous-flow left ventricular assist device (50 HeartMate II [Abbott Medical, Abbott Park, Ill], 38 DuraHeart [Terumo Heart, Ann Arbor, Mich], 33 Jarvik2000 [Jarvik Heart, New York, NY], 23 EVAHEART [Sun Medical, Moriyama City, Japan], 14 HeartWare [Framingham, Mass]) implantation in our institution. We analyzed the risk factors for a symptomatic stroke within 90 days after left ventricular assist device implantation. Stroke occurred in 28 patients in the acute phase after left ventricular assist device implantation. Multivariate analysis revealed that low cardiac output (odds ratio, 0.25; 0.07-0.92; P = .024) during postoperative 12 to 24 hours was the only independent risk factor for stroke in the acute phase. Patients with stroke in the acute phase had higher serum lactate dehydrogenase levels at any point until postoperative 14 days. Patients with the HeartMate II device particularly showed a statistically significant negative relationship between cardiac output during postoperative 12 to 24 hours and serum lactate dehydrogenase levels at postoperative 14 days (r = -0.313, P = .03). Our study demonstrated that patients with perioperative lower cardiac output and higher lactate dehydrogenase level developed stroke in the acute phase after left ventricular assist device implantation. These results suggested that maintenance of sufficient left ventricular assist device flow is important in prevention of stroke, which may be related to subclinical pump thrombosis.

Identifiants

pubmed: 30060931
pii: S0022-5223(18)31765-3
doi: 10.1016/j.jtcvs.2018.06.031
pii:
doi:

Substances chimiques

L-Lactate Dehydrogenase EC 1.1.1.27

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

259-267.e1

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2018 The American Association for Thoracic Surgery. Published by Elsevier Inc. All rights reserved.

Auteurs

Takaaki Samura (T)

Department of Cardiovascular Surgery, Osaka University Graduate School of Medicine, Osaka, Japan.

Daisuke Yoshioka (D)

Department of Cardiovascular Surgery, Osaka University Graduate School of Medicine, Osaka, Japan.

Koichi Toda (K)

Department of Cardiovascular Surgery, Osaka University Graduate School of Medicine, Osaka, Japan.

Ryoto Sakaniwa (R)

Department of Public Health, Osaka University Graduate School of Medicine, Osaka, Japan.

Mikito Shimizu (M)

Department of Neurology, Osaka University Graduate School of Medicine, Osaka, Japan.

Shigeru Miyagawa (S)

Department of Cardiovascular Surgery, Osaka University Graduate School of Medicine, Osaka, Japan.

Yasushi Yoshikawa (Y)

Department of Cardiovascular Surgery, Osaka University Graduate School of Medicine, Osaka, Japan.

Hiroki Hata (H)

Department of Cardiovascular Surgery, Osaka University Graduate School of Medicine, Osaka, Japan.

Shunsuke Saito (S)

Department of Cardiovascular Surgery, Osaka University Graduate School of Medicine, Osaka, Japan.

Yasushi Sakata (Y)

Department of Cardiology, Osaka University Graduate School of Medicine, Osaka, Japan.

Yoshiki Sawa (Y)

Department of Cardiovascular Surgery, Osaka University Graduate School of Medicine, Osaka, Japan. Electronic address: sawa-p@surg1.med.osaka-u.ac.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH